Emily Pittman
About
Emily Pittman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Emily Pittman has authored 22 papers receiving a total of 508 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Emily Pittman's work include Advanced Breast Cancer Therapies (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Emily Pittman is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Emily Pittman collaborates with scholars based in United States, Australia and Canada. Emily Pittman's co-authors include Karen Messer, Minya Pu, Kathryn A. Gold, Ezra E.W. Cohen, Ruifeng Chen, Assuntina G. Sacco, Julie Bykowski, Paul Swiecicki, Deborah Jean Lee Wong and Francis P. Worden and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.
In The Last Decade
Emily Pittman
21 papers receiving 504 citations
Hit Papers
Peers
Emily Pittman
Hoa Q. Trummell United States
Neha Luthar United States
W. H. Miller United States
Frank Tsai United States
Meghan Nechrebecki United States
Konstantinos Tsaparikos United States
Cristina Quero Spain
Varalakshmi Janamanchi United States
Katherine R. Singleton United States
Roza Zandi Denmark
Citations per year, relative to Emily Pittman Emily Pittman (= 1×)
peers
Hoa Q. Trummell
Countries citing papers authored by Emily Pittman
Since
Specialization
Citations
This map shows the geographic impact of Emily Pittman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Pittman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Pittman more than expected).
Fields of papers citing papers by Emily Pittman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Emily Pittman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Pittman. The network helps show where Emily Pittman may publish in the future.
Co-authorship network of co-authors of Emily Pittman
This figure shows the co-authorship network connecting the top 25 collaborators of Emily Pittman. A scholar is included among the top collaborators of Emily Pittman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Pittman. Emily Pittman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shatsky, Rebecca, Teresa Helsten, Richard B. Schwab, et al.. (2024). A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer. Breast Cancer Research. 26(1). 32–32.
2.
Dennis, Michael J., Assuntina G. Sacco, Yuchen Qi, et al.. (2022). A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oral Oncology. 135. 106219–106219.
3.
Liu, Lin, Minya Pu, Emily Pittman, et al.. (2022). Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma: Stage 2 interim results.. Journal of Clinical Oncology. 40(16_suppl). 8041–8041.
4.
Sacco, Assuntina G., Ruifeng Chen, Francis P. Worden, et al.. (2021). Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. The Lancet Oncology. 22(6). 883–892.
5.
Shatsky, Rebecca, Karen Messer, Teresa Helsten, et al.. (2021). Abstract LB255: Phase 1b trial of cirmtuzumab and paclitaxel for locally advanced, unresectable and metastatic breast cancer. Tumor Biology. LB255–LB255.
6.
Ryan, Stephen, Jing Zhang, Michael A. Liss, et al.. (2020). Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. Journal of Translational Medicine. 18(1). 214–214.
7.
Shatsky, Rebecca, Richard B. Schwab, Teresa Helsten, et al.. (2020). Abstract P3-10-18: Phase 1b trial of cirmtuzumab and paclitaxel for locally advanced, unresectable and metastatic breast cancer. Cancer Research. 80(4_Supplement). P3–10.
8.
Sacco, Alessandra, Rong Chen, Debasis Ghosh, et al.. (2020). An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis. International Journal of Radiation Oncology*Biology*Physics. 106(5). 1121–1122.
9.
Heyman, Benjamin, Michael Y. Choi, Emanuela M. Ghia, et al.. (2020). Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax. Blood. 136(Supplement 1). 13–13.
10.
Pu, Minya, Karen Messer, Sherri R. Davies, et al.. (2019). Research-based PAM50 signature and long-term breast cancer survival. Breast Cancer Research and Treatment. 179(1). 197–206.
11.
Sacco, Assuntina G., Ruifeng Chen, Deborah Jean Lee Wong, et al.. (2019). An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis.. Journal of Clinical Oncology. 37(15_suppl). 6033–6033.
12.
Natarajan, Loki, Minya Pu, Sherri R. Davies, et al.. (2019). miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study. Cancer Epidemiology Biomarkers & Prevention. 28(9). 1525–1533.
13.
Choi, Michael Y., George F. Widhopf, Emanuela M. Ghia, et al.. (2018). Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell stem cell. 22(6). 951–959.e3.
14.
Ryan, Stephen, Christina Jamieson, Ahmed Shabaik, et al.. (2018). MP70-20 B CELL CONCENTRATION IN HIGH RISK PROSTATE CANCER SPECIMENS AFTER NEOADJUVANT RITUXIMAB. The Journal of Urology. 199(4S).
15.
Sacco, Assuntina G., Karen Messer, Ruifeng Chen, et al.. (2018). An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of the interim safety analysis.. Journal of Clinical Oncology. 36(15_suppl). 6037–6037.
16.
Choi, Michael Y., George F. Widhopf, Jian Yu, et al.. (2017). Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab. Blood. 130(Suppl_1). 829–829.
17.
Choi, Michael Y., Catriona Jamieson, George F. Widhopf, et al.. (2016). A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis. Clinical Lymphoma Myeloma & Leukemia. 16. S44–S44.
18.
Choi, Michael Y., George F. Widhopf, Jian Yu, et al.. (2016). Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia. Blood. 128(22). 3224–3224.
19.
Marcet‐Palacios, Marcelo, C. Ewen, Emily Pittman, et al.. (2014). Design and characterization of a novel human Granzyme B inhibitor. Protein Engineering Design and Selection. 28(1). 9–17.
20.
Pörzgen, Peter, et al.. (2008). Isolation and Structure Determination of Malevamide E, a Dolastatin 14 Analogue, from the Marine Cyanobacterium Symploca laete-viridis. Journal of Natural Products. 71(5). 750–754.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hoa Q. Trummell Breakdown of academic impact, for papers by Neha Luthar Breakdown of academic impact, for papers by W. H. Miller Breakdown of academic impact, for papers by Frank Tsai Breakdown of academic impact, for papers by Meghan Nechrebecki Breakdown of academic impact, for papers by Konstantinos Tsaparikos Breakdown of academic impact, for papers by Cristina Quero Breakdown of academic impact, for papers by Varalakshmi Janamanchi Breakdown of academic impact, for papers by Katherine R. Singleton Breakdown of academic impact, for papers by Roza Zandi